Nykode Therapeutics AS (FRA:5VB) Tariff Resilience Score: 5/10 (As of Jun. 28, 2026)


FRA:5VB Nykode Therapeutics AS FRA:5VB
37 GF Score
Price €0.25
GF Value €0.49
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Nykode Therapeutics AS Tariff Resilience Score?

Nykode Therapeutics AS FRA:5VB -0.61% 37 Tariff Resilience Score is 5 as of Jun. 28, 2026. GuruFocus rates FRA:5VB with a GF Score™ of 37/100 and a GF Value™ of €0.49 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,376 Biotechnology companies, Nykode Therapeutics AS ranks better than 62.21% on this metric.

Nykode Therapeutics AS has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Nykode Therapeutics AS has Nykode Therapeutics AS, a biotech firm, could be moderately affected by tariffs on pharmaceutical imports/exports. Its reliance on global supply chains for raw materials and manufacturing could pose risks, though industry-specific exemptions may apply.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Nykode Therapeutics AS might have Average Resilient.

Nykode Therapeutics AS  (FRA:5VB) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Nykode Therapeutics AS Tariff Resilience Score Related Terms

FRA:5VB vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Nykode Therapeutics AS's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nykode Therapeutics AS Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nykode Therapeutics AS's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Nykode Therapeutics AS's Tariff Resilience Score falls into.


FRA:5VB
37GF Score
Nykode Therapeutics AS FRA:5VB
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Nykode Therapeutics AS (FRA:5VB) has a Tariff Resilience Score of 5 as of Jun. 28, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Nykode Therapeutics AS ranks #520 out of 1376 companies in the Biotechnology industry, placing it in the top 37.8%.
Is Nykode Therapeutics AS's Tariff Resilience Score too high?
Nykode Therapeutics AS's current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Nykode Therapeutics AS's value of 5 is 25% above this industry median. Based on the distribution chart, Nykode Therapeutics AS ranks #520 out of 1376 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nykode Therapeutics AS has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nykode Therapeutics AS ranks #520 out of 1376 companies for Tariff Resilience Score. This puts Nykode Therapeutics AS in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Nykode Therapeutics AS's value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,376 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nykode Therapeutics AS's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nykode Therapeutics AS's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (FRA:5VB) is currently considered Possible Value Trap. The stock's GF Value™ is €0.49, compared to a current price of €0.25 — trading 50% below its estimated fair value. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Nykode Therapeutics AS's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Nykode Therapeutics AS (FRA:5VB), the current Tariff Resilience Score is 5 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nykode Therapeutics AS (FRA:5VB) Overvalued in 2026?

Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued. The current stock price of €0.25 is trading 50% below its estimated GF Value™ of €0.49. GuruFocus considers Nykode Therapeutics AS to be Possible Value Trap.

Key valuation signals for FRA:5VB:

  • Tariff Resilience Score: 5
  • GF Value™: €0.49 vs. price of €0.25 (50% below fair value)
  • GF Score™: 37/100 with 2 warning signs
  • Industry Position: 25% above the Biotechnology median (#520 of 1376)

No single metric tells the full story. See the FRA:5VB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nykode Therapeutics AS Business Description

Address Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
37GF Score

Get the complete analysis for FRA:5VB

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.25
Price
€0.49
GF Value